Actinogen Medical Limited (ASX:ACW)
Australia
· Delayed Price · Currency is AUD 0.0270
-0.0010 (-3.57%)
Apr 28, 2025, 4:10 PM AEST
Actinogen Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Other Revenue | 9.02 | 9.93 | 4.89 | 3.64 | 1.98 | 3.52 | Upgrade
|
| Revenue | 9.02 | 9.93 | 4.89 | 3.64 | 1.98 | 3.52 | Upgrade
|
| Revenue Growth (YoY) | 88.25% | 103.18% | 34.28% | 83.47% | -43.58% | -27.69% | Upgrade
|
| Gross Profit | 9.02 | 9.93 | 4.89 | 3.64 | 1.98 | 3.52 | Upgrade
|
| Selling, General & Admin | 5.95 | 5.93 | 5.05 | 3.27 | 2.82 | 2.77 | Upgrade
|
| Research & Development | 11.17 | 15.54 | 8.9 | 8.21 | 2.41 | 5.54 | Upgrade
|
| Operating Expenses | 18.99 | 23.19 | 15.87 | 13.17 | 5.9 | 8.91 | Upgrade
|
| Operating Income | -9.96 | -13.26 | -10.99 | -9.53 | -3.92 | -5.4 | Upgrade
|
| Interest Expense | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.43 | 0.29 | 0.37 | 0.04 | 0.03 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.09 | -0.06 | -0.12 | 0.01 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -9.66 | -13.04 | -10.75 | -9.5 | -3.92 | -5.33 | Upgrade
|
| Pretax Income | -9.66 | -13.04 | -10.75 | -9.5 | -3.92 | -5.33 | Upgrade
|
| Net Income | -9.66 | -13.04 | -10.75 | -9.5 | -3.92 | -5.33 | Upgrade
|
| Net Income to Common | -9.66 | -13.04 | -10.75 | -9.5 | -3.92 | -5.33 | Upgrade
|
| Shares Outstanding (Basic) | 2,601 | 2,174 | 1,802 | 1,717 | 1,405 | 1,118 | Upgrade
|
| Shares Outstanding (Diluted) | 2,601 | 2,174 | 1,802 | 1,717 | 1,405 | 1,118 | Upgrade
|
| Shares Change (YoY) | 35.04% | 20.69% | 4.92% | 22.20% | 25.69% | 1.43% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | Upgrade
|
| Free Cash Flow | -8.73 | -16.96 | -8.73 | -9.52 | -1.73 | -2.88 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -110.44% | -133.47% | -224.74% | -261.90% | -197.56% | -153.44% | Upgrade
|
| Profit Margin | -107.03% | -131.34% | -219.98% | -260.91% | -197.32% | -151.59% | Upgrade
|
| Free Cash Flow Margin | -96.75% | -170.76% | -178.70% | -261.53% | -87.20% | -81.86% | Upgrade
|
| EBITDA | -9.64 | -12.92 | -10.66 | -9.21 | -3.6 | -5.08 | Upgrade
|
| EBITDA Margin | -106.83% | -130.10% | -218.10% | -253.12% | -181.39% | -144.41% | Upgrade
|
| D&A For EBITDA | 0.33 | 0.33 | 0.32 | 0.32 | 0.32 | 0.32 | Upgrade
|
| EBIT | -9.96 | -13.26 | -10.99 | -9.53 | -3.92 | -5.4 | Upgrade
|
| EBIT Margin | -110.44% | -133.47% | -224.74% | -261.90% | -197.56% | -153.44% | Upgrade
|
| Revenue as Reported | 9.45 | 10.22 | 5.25 | 3.68 | 2.01 | 3.61 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.